Study of ASN004 in Patients With Advanced Solid Tumors

Summary

Participants in this study will receive ASN004 once every 3 or 4 weeks by intravenous infusion. The ASN004 dosing schedule may be modified based on emerging data and Safety Review Committee decision. The study will test various doses of ASN004 to find out the highest safe dose to test in future trials. Eligible subjects will be sequentially enrolled in cohorts at escalated doses.

Timeline

Start

2022-04-08

Primary completion

2024-05-08

Completion

2024-05-08

Drugs

Indications